Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299526 | 0.95 | USP2 (0.41) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL8152684 | 0.92 | USP2 (0.40) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL12184487 | 0.88 | GPR119 (0.44) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL20355326 | 0.86 | USP2 (0.41) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL2305761 | 0.84 | USP2 (0.38) | USP2SMN1; SMN2DDB1CRBNMAPT | |
| SCHEMBL3493829 | 0.82 | GPR119 (0.44) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL4258590 | 0.81 | LMNA (0.40) | DDB1CRBNCHRM2LMNAADRA2A | |
| SCHEMBL2143219 | 0.81 | USP2 (0.43) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL17324894 | 0.80 | USP2 (0.42) | USP2SMN1; SMN2GPR119DDB1CRBN | |
| SCHEMBL31299486 | 0.80 | USP2 (0.49) | USP2SMN1; SMN2GPR119DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | TYRA BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | DOMAIN THERAPEUTICS (FR) | 2025-10-16 | — | — | US | disclosed |
| EP-4532496-A1 | NOVEL PAR-2 INHIBITORS | Domain Therapeutics (FR) | 2025-04-09 | — | — | EP | disclosed |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-119384420-A | Novel PAR-2 inhibitors | 多曼治疗学公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-119320397-A | SSTR5-TGR5 double-effect compound, and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-01-17 | — | — | CN | disclosed |
| US-20240317735-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2024-09-26 | — | — | US | disclosed |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | TYRA BIOSCIENCES, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-20240252506-A1 | COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2024-08-01 | — | — | US | disclosed |
| WO-2011101409-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| EP-1910381-B1 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | GRUENENTHAL GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | GRUENENTHAL GMBH (DE) | 2009-04-23 | — | — | US | disclosed |
| WO-2007000325-A2 | SUBSTITUTED 1-OXA-3,8-DIAZASPIRO[4.5]-DECAN-2-ON- COMPOUNDS AND THE USE THEREOF FOR PRODUCING DRUGS | Grünenthal GmbH (DE) | 2007-01-04 | — | — | WO | disclosed |
| EP-1087770-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO INC (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1087770-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 2001-04-04 | — | — | EP | disclosed |
| US-6172076-B1 | HETEROCYCLE-SUBSTITUTED 1,3,8-TRIAZASPIRO(4,5)DECANE DERIVATIVES; TREATING ARTERIOSCLEROSIS | MERCK & CO., INC. | 2001-01-09 | — | — | US | disclosed |
| WO-1999065494-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105290-A1 | Substituted 1-oxa-3,8-diazaspiro[4.5]-decan-2-one-Compounds and the Use Thereof for Producing Drugs | DDO, DAO, OTC | USP2 2747/4885SMN1; SMN2 3067/4885GPR119 2075/4885 |
| US-12071428-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | USP2 3813/4885SMN1; SMN2 3467/4885GPR119 438/4885 |
| US-20240317735-A1 | HYDROISOQUINOLINE OR HYDRONAPHTHYRIDINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HRH3, H1-3, HRH4 | USP2 4641/4885SMN1; SMN2 4207/4885GPR119 1548/4885 |
| US-20250320224-A1 | NOVEL PAR-2 INHIBITORS | F2RL1, F2R, F2RL3 | USP2 1401/4885SMN1; SMN2 1138/4885GPR119 974/4885 |
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | C3AR1, LTB4R, C5 | USP2 3717/4885SMN1; SMN2 4255/4885GPR119 2096/4885 |
| US-20250340533-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | USP2 3813/4885SMN1; SMN2 3467/4885GPR119 438/4885 |
| US-12264149-B2 | Indazole compounds as kinase inhibitors | FGFR1, FGFR2, FGFR3 | USP2 3813/4885SMN1; SMN2 3467/4885GPR119 438/4885 |
| US-20240252506-A1 | COMPOUNDS FOR TREATMENT OF BACTERIAL INFECTION | C3AR1, LTB4R, C5 | USP2 3090/4885SMN1; SMN2 4300/4885GPR119 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.